Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Gyeong-Won | - |
dc.contributor.author | Go, Se-Il | - |
dc.contributor.author | Kim, Seok-Hyun | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Kim, Yu Ri | - |
dc.contributor.author | Oh, Sukjoong | - |
dc.contributor.author | Kim, Sung-Yong | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Lee, Hyewon | - |
dc.contributor.author | Song, Moo Kon | - |
dc.date.accessioned | 2022-07-15T23:18:01Z | - |
dc.date.available | 2022-07-15T23:18:01Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2015-04 | - |
dc.identifier.issn | 1042-8194 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/157457 | - |
dc.description.abstract | We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma(SN-DLBCL)treatedwithrituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21(26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | INFORMA HEALTHCARE | - |
dc.title | Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Moo Kon | - |
dc.identifier.doi | 10.3109/10428194.2014.946027 | - |
dc.identifier.scopusid | 2-s2.0-84929077148 | - |
dc.identifier.wosid | 000353612700032 | - |
dc.identifier.bibliographicCitation | LEUKEMIA & LYMPHOMA, v.56, no.4, pp.1020 - 1026 | - |
dc.relation.isPartOf | LEUKEMIA & LYMPHOMA | - |
dc.citation.title | LEUKEMIA & LYMPHOMA | - |
dc.citation.volume | 56 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1020 | - |
dc.citation.endPage | 1026 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | NON-HODGKIN-LYMPHOMA | - |
dc.subject.keywordPlus | NERVOUS-SYSTEM INVOLVEMENT | - |
dc.subject.keywordPlus | STUDY-GROUP DSHNHL | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | AGGRESSIVE LYMPHOMA | - |
dc.subject.keywordPlus | MALIGNANT-LYMPHOMAS | - |
dc.subject.keywordPlus | PARANASAL SINUSES | - |
dc.subject.keywordPlus | CNS PROPHYLAXIS | - |
dc.subject.keywordPlus | CHOP | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordAuthor | Diffuse large cell lymphomas | - |
dc.subject.keywordAuthor | nasal cavities | - |
dc.subject.keywordAuthor | paranasal sinus | - |
dc.subject.keywordAuthor | rituximab | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.3109/10428194.2014.946027 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.